Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX-2044 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX-2044 1.5 mg | EXPERIMENTAL | - |
| MBX-2044 4.5 mg | EXPERIMENTAL | - |
| MBX-2044 15 mg | EXPERIMENTAL | - |
| MBX-2044 30 mg | EXPERIMENTAL | - |
| MBX-2044 60 mg | EXPERIMENTAL | - |
| MBX-2044 90 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MBX-2044 | DRUG | MBX-2044 1.5 mg one capsule daily for 14 days |
| Placebo for MBX-2044 | DRUG | Placebo Intervention |
Inclusion Criteria: * Type 2 diabetes previously controlled with up to one or two non-TZD hypoglycemic agents including sulfonylureas (e.g., glyburide, glipizide, glimeprimide), meglitinides (e.g., Prandin®, Starlix®), metformin (e.g., Glucophage®), α-glucosidase inhibitors (e.g.,acarbose, miglitol...
MBX-2044 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It has been evaluated in a Phase 2 clinical trial in adults with the condition. It is not approved for any indication and remains in clinical development.
MBX-2044 targets PPARG, also known as peroxisome proliferator-activated receptor gamma. It is classified as a modulator of this target. PPARG is a nuclear receptor involved in regulating glucose and lipid metabolism, which is relevant to Type 2 Diabetes Mellitus.
MBX-2044 is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. The company is the sponsor of the clinical program evaluating the compound in Type 2 Diabetes Mellitus.
MBX-2044 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
MBX-2044 has been studied in one clinical trial, NCT00422487, titled a Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes. The Phase 2 trial was completed, enrolled 60 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.